Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

147 results
Display

Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis

Oh SJ, Shin GY, Soh H, Lee JG, Im JP, Eun CS, Lee KM, Park DI, Han DS, Kim HJ, Lee CK

Background/Aims: Infliximab (IFX) has proven effective as rescue therapy in steroid-refractory acute severe ulcerative colitis (ASUC), however, the long-term real-world data are scarce. Our study aimed to assess the long-term...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018

Aniwan S, Limsrivilai J, Pongprasobchai S, Pausawasdi N, Prueksapanich P, Kongtub N, Rerknimitr R

Background/Aims: The incidence of ulcerative colitis (UC) in Thailand (crude incidence rate of 0.28 per 100,000 persons) is much lower than in the West. The burden of UC varies in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry

Sood A, Kaur K, Mahajan R, Midha V, Singh A, Sharma S, Puri AS, Goswami B, Desai D, Pai CG, Peddi K, Philip M, Kochhar R, Nijhawan S, Bhatia S, Rao NS

Background/Aims: The national registry for inflammatory bowel disease (IBD) was designed to study epidemiology and prescribing pattern of treatment of IBD in India. Methods: A multicenter, cross-sectional, prospective registry was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease

Hong SW, Park J, Yoon H, Yang HR, Shin CM, Park YS, Kim N, Lee DH, Kim JS

Background/Aims: Combination therapy with immunomodulators (IMMs) was proposed as a strategy to prevent the development of loss of response (LOR) to anti-tumor necrosis factor (TNF) for patients with inflammatory bowel...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pyoderma Gangrenosum of the Chest Wall in a Male Patient with Ulcerative Colitis

Choi MK, Jeong YJ, Hong SG

Ulcerative colitis, an inflammatory bowel disease, often exhibits extra-intestinal manifestations including various dermatological problems. Pyoderma gangrenosum (PG) is a painful ulcerative cutaneous disorder characterized by the development of rapidly enlarging...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy

Hayashi R, Ueno Y, Tanaka S, Onishi K, Takasago T, Wakai M, Naito T, Sasaki K, Doi S, Masaki T, Chayama K

Background/Aims: Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal tract. Some patients with this condition have been reported to present with immunoglobulin A nephropathy (IgAN), a renal...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?

Theodoraki E, Orfanoudaki E, Foteinogiannopoulou K, Legaki E, Gazouli M, Koutroubakis IE

Background/Aims: The measurement of infliximab trough levels (IFX-TLs) in patients with inflammatory bowel disease (IBD) is performed to optimize treatment. However, the association between the development of adverse events (AEs)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pouchitis in inflammatory bowel disease: a review of diagnosis, prognosis, and treatment

Akiyama S, Rai V, Rubin DT

Patients with inflammatory bowel disease (IBD) occasionally need a restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) because of medically refractory colitis or dysplasia/cancer. However, pouchitis may develop in up to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study

Ooi CJ, Hilmi IN, Kim HJ, Jalihal U, Wu DC, Demuth D, Lindner D, Adsul S

Background/Aims: The efficacy and safety of vedolizumab in moderate to severely active ulcerative colitis (UC) have been demonstrated in the GEMINI 1 study (NCT00783718). This post-hoc exploratory analysis sought to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease

Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T

Background/Aims: Vedolizumab is indicated for moderately-to-severely active ulcerative colitis (UC) and Crohn’s disease (CD). Because multiple factors may result in different pharmacokinetics and clinical efficacies, understanding determinants of vedolizumab clearance...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Whipple disease mimicking inflammatory bowel disease

Tatsuki M, Ishige T, Igarashi Y, Hatori R, Hokama A, Hirato J, Muise A, Takizawa T, Arakawa H

Whipple disease is a systemic chronic infection caused by Tropheryma whipplei. Although chronic diarrhea is a common gastrointestinal symptom, diagnosis is often difficult because there are no specific endoscopic findings,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis

Jeong Y, Jeon SR, Kim HG, Moon JR, Lee TH, Jang JY, Cho JH, Park JS, Park H, Lee Kh, Kim JO, Lee JS, Ko BM, Park S

Background/Aims: Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) can serve as biomarkers for diagnosing and assessing disease activity in ulcerative colitis (UC). We investigated their clinical...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis

Hibi T, Kamae I, Pinton P, Ursos L, Iwakiri R, Hather G, Patel H

Background/Aims: Several biologic therapies are approved in Japan to treat moderately to severely active ulcerative colitis (UC), but there are no published comparative efficacy studies in a Japanese population. We...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Quality of life in inflammatory bowel diseases: it is not all about the bowel

Keller R, Mazurak N, Fantasia L, Fusco S, Malek NP, Wehkamp J, Enck P, Klag T

Background/Aims: The inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn’s disease (CD) are chronic diseases mostly affecting young patients. As they are diseases accompanying patients for their entire life,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Capsule endoscopy in inflammatory bowel disease: when and how

Hilmi I, Kobayashi T

Capsule endoscopy (CE) is emerging as an important investigation in inflammatory bowel disease (IBD); common types include the standard small bowel CE and colon CE. More recently, the pan-enteric CE...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Incidental benefits after fecal microbiota transplant for ulcerative colitis

Mahajan R, Midha V, Singh A, Mehta V, Gupta Y, Kaur K, Sudhakar R, Singh Pannu A, Singh D, Sood A

Gut dysbiosis can result in several diseases, including infections (Clostridium difficile infection and infectious gastroenteritis), autoimmune diseases (inflammatory bowel disease, diabetes, and allergic disorders), behavioral disorders and other conditions like...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease

Alrajhi S, Germain P, Martel M, Lakatos P, Bessissow T, Al-Taweel T, Afif W

Background/Aims: Latent tuberculosis screening is mandatory prior to initiating anti-tumor necrosis factor (anti-TNF) medications. Guidelines recommend interferon-gamma release assays (IGRA) as first line screening method for the general population. Studies...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea

Moon JR, Lee CK, Hong SN, Im JP, Ye BD, Cha JM, Jung SA, Lee KM, Park DI, Jeen YT, Park YS, Cheon JH, Kim H, Seo B, Kim Y, Kim HJ, the MOSAIK study group of the Korean Association for the Study of Intestinal Diseases (KASID)

Background/Aims: Limited data are available regarding psychosocial distress at the time of diagnosis of ulcerative colitis (UC). We investigated the psychosocial burden and factors related to poor health-related quality of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term Outcomes of Adalimumab Therapy in Korean Patients with Ulcerative Colitis: A Hospital-Based Cohort Study

Oh EH, Kim J, Ham N, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Ye BD

Background/Aims: Studies on long-term outcomes of adalimumab therapy in non-Caucasian patients with ulcerative colitis (UC) are lacking. Methods: We analyzed long-term outcomes of Korean UC patients treated with adalimumab at the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Changes in prevalence and perception of complementary and alternative medicine use in Korean inflammatory bowel disease patients: results of an 8-year follow-up survey

Lee SH, Chang K, Seo KS, Cho YK, Song EM, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH

Background/Aims: The use of complementary and alternative medicine (CAM) is a global phenomenon, including inflammatory bowel disease (IBD) patients. We aimed to assess the change in prevalence and patterns of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr